CSL Limited
CSL
Rang in aandelen
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Aandeelprijs
$138.33
Marktkapitalisatie
$66.38B
Verandering (1 dag)
-0.22%
Verandering (1 jaar)
-3.31%
Land
AU
Handel CSL Limited (CSL)
Categorie
Healthcare
Omzet van CSL Limited (CSL)
Omzet in Jun 2026 TTM: $15.74B
Volgens de laatste financiële rapporten van CSL Limited bedraagt de huidige omzet van het bedrijf (TTM) $15.74B. In 2024 behaalde het bedrijf een omzet van $14.69B een stijging ten opzichte van de omzet in het jaar 2023, die $13.17B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van CSL Limited van 2000 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $15.74B | 2.04% |
| 2025 | $15.43B | 5.04% |
| 2024 | $14.69B | 11.51% |
| 2023 | $13.17B | 25.55% |
| 2022 | $10.49B | 1.56% |
| 2021 | $10.33B | 9.84% |
| 2020 | $9.41B | 13.08% |
| 2019 | $8.32B | 11.54% |
| 2018 | $7.46B | 6.28% |
| 2017 | $7.02B | 15.81% |
| 2016 | $6.06B | 11.00% |
| 2015 | $5.46B | 8.91% |
| 2014 | $5.01B | 10.79% |
| 2013 | $4.52B | -2.44% |
| 2012 | $4.64B | -3.37% |
| 2011 | $4.80B | 49.63% |
| 2010 | $3.21B | 6.25% |
| 2009 | $3.02B | -7.53% |
| 2008 | $3.26B | 42.87% |
| 2007 | $2.28B | 45.52% |
| 2006 | $1.57B | -1.58% |
| 2005 | $1.60B | 98.59% |
| 2004 | $803.28M | 36.45% |
| 2003 | $588.71M | 38.88% |
| 2002 | $423.90M | -2.21% |
| 2001 | $433.49M | 0.00% |
| 2000 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | -19.82% |
US
|
|
| $2.23B | -85.85% |
US
|
|
| - | - |
CH
|
|
| $6.02B | -61.76% |
NL
|
|
| $10.11B | -35.78% |
BE
|
